SPOTLIGHT -
Hydromorphone tablets 2, 4, and 8 mg (equiv to Dilaudid tablets)
What We’re Reading: Sickle Cell Disease and Exa-cel Gene Therapy
New Lung Cancer Drug Augtyro is Now Available
Augtyro, approved last month, launched with a month wholesale acquisition $29,000 for patients with ROS1-positive non-small cell lung cancer.
FDA Approves Fabhalta, an Oral Treatment for Rare Blood Disorder
Fabhalta was approved to treat patients with paroxysmal nocturnal hemoglobinuria and will have a wholesale acquisition cost of $550,000 per year.
FDA Approves Jaypirca for Leukemia/Lymphoma Indication
Jaypirca is also approved to treat mantle cell lymphoma. It has a list price of $21,000 for a 30-day supply.
Pfizer Stops GLP-1 Obesity Trial Because of High Discontinuation Rates
Twice-daily danuglipron was being studied in a phase 2 study in adults with obesity. Pfizer is now conducting a pharmacokinetic study for a once-daily formulation.
FDA Sets Review Date for Zoryve in Atopic Dermatitis
The FDA has set a date of July 07, 2024, for Zorvye 0.15% for adults and children six and up with the chronic skin disease atopic dermatitis.
